Boston, MA -- (ReleaseWire) -- 06/24/2014 -- A more liberal attitude among youth and young adults and easier access to OTC analgesics was the instrumental fact behind the category's growth in 2013. Younger people seem to have a lower threshold rate than older people. In addition, it is the common remedy against hangover pains. There is some concern both from The Norwegian Medicines Authority and other medical professionals, but this does not seem to discourage consumers from buying it.
Within analgesics, Weifa AS enjoyed value share of 79% in 2013. The reason for this outstanding dominance is that Weifa produces the two best-selling brands in Norwegian consumer health, Paracet and Ibux. Both products have been present for many years, and are often perceived by the Norwegian public as synonymous with an analgesic. Weifa also has a strong confidence among Norwegian consumers, being a domestic company with a long history in pharmaceuticals.
View Full Report Details and Table of Contents
In December 2013, The Norwegian Medicines Authority put forward new regulations for pharmaceutical ingredient diclofenac. Among the new regulations, the most important are a restriction on packaging size, more visible label warnings and that the pharmacy personal will receive training on the risk of using diclofenac over a longer time period. The reason for this measure is the increased risk of cardiovascular diseases that the long-term use of diclofenac induces. The only and highly successful diclofenac brand available in 2013, Voltarol, might be affected by the new regulation. This might lead to a shift in the preferred brand among consumers, especially among those with muscular and joint pains. Also important to note is that this only affects systemic analgesics.
Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Norway with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Analgesics industry in Norway, our research will save you time and money while empowering you to make informed, profitable decisions.
The Analgesics in Norway market research report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volumes and values, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent market research methodology, conducted in-country
Our market research reports answer questions such as:
- What is the market size of Analgesics in Norway?
- What are the major brands in Norway?
- Are combination products with acetaminophen still popular?
Reasons to Get this Report
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Analgesics in Portugal
- Analgesics in Israel
- Analgesics in Indonesia
- Analgesics in the United Kingdom
- Analgesics in South Korea
- Analgesics in India
- Analgesics in Ireland
- Analgesics in Bosnia-Herzegovina
- Analgesics in the US
- Analgesics in Hungary